Non-hemolytic lazaroid parenteral formulation

Details Non-hemolytic lazaroid parenteral formulation Non-hemolytic lazaroid parenteral formulation

1988-10-28

1990-11-06

Lipovsky, Joseph A.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514922, A61K 3158

Patent

active

049686755

ABSTRACT:
16.alpha.-Methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperaziny l]pregna-1,4,9(11)-triene-3,20-dione monomethanesulfonate causes hemolysis when injected. However, when formulated with a citric acid/sodium citrate both the hemolysis and hypotension side effects are prevented.

REFERENCES:
patent: 4497805 (1985-02-01), Phillipps et al.
patent: 4515786 (1985-05-01), Phillipps et al.
patent: 4664916 (1987-05-01), Fukuda
Cancer Chemotherapy Reports, Part I, 58, 171 (1974).
J. Pharm. Exptl. Ther., 196, 525 (1976).

Affiliated with

Also associated with

Rating

Non-hemolytic lazaroid parenteral formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Non-hemolytic lazaroid parenteral formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-hemolytic lazaroid parenteral formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1306966